E-LIB Suche - Ergebnisse für: SAN-MIGUEL Jesus

1

Practical Aspects of Immunotherapy: A Report from the 20th ..:

Raje, Noopur S. ; Cohen, Adam D. ; Patel, Krina K....
Clinical Lymphoma Myeloma and Leukemia. 24 (2024) 6 - p. 350-357 , 2024

Link: https://doi.org/10.1016/..

2

Mapping global forest cover of the year 2020 to support the..

EUR, 31888

Bourgoin, Clement ; Ameztoy, Iban ; Verhegghen, Astrid... , 2024

Link: https://op.europa.eu/pub..

3

Oral Abstract: MM-304 Efficacy Outcomes and Characteristics..:

Munshi, Nikhil ; Pavia, Bruno ; Martin, Thomas...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S146 , 2023

Link: https://doi.org/10.1016/..

4

P-016 Disparities in access and practice patterns of BCMA-d..:

Hassan, Hamza ; Samur, Mehmet ; Cohen, Adam...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S41-S42 , 2023

Link: https://doi.org/10.1016/..

5

MM-162 Durability of Responses With Biweekly Dosing of Tecl..:

Usmani, Saad Z ; Karlin, Lionel ; Benboubker, Lotfi...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S477 , 2023

Link: https://doi.org/10.1016/..

6

MM-304 Efficacy Outcomes and Characteristics of Patients Wi..:

Munshi, Nikhil ; Pavia, Bruno ; Martin, Thomas...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S487-S488 , 2023

Link: https://doi.org/10.1016/..

7

Prevention and management of adverse events during treatmen..:

Ludwig, Heinz ; Terpos, Evangelos ; van de Donk, Niels...
The Lancet Oncology. 24 (2023) 6 - p. e255-e269 , 2023

Link: https://doi.org/10.1016/..

8

OA-47 Additional analysis of CARTITUDE-4: Cilta-cel vs stan..:

Manier, Salomon ; San-Miguel, Jesús ; Dhakal, Binod...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S29-S30 , 2023

Link: https://doi.org/10.1016/..

9

P-045 Early treatment with bispecific T-cell redirectors (t..:

Rodriguez-Otero, Paula ; Mateos, Maria-Victoria ; Palacios, Juan José Lahuerta...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S59-S60 , 2023

Link: https://doi.org/10.1016/..

10

P-034 Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA × CD..:

Costa, Luciano ; Bar, Noffar ; Mateos, Maria-Victoria...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S52-S53 , 2023

Link: https://doi.org/10.1016/..

11

P-400 An immune atlas of the dysfunctional cellular and ant..:

Martin-Sanchez, Esperanza ; Guerrero, Camila ; Tamariz-Amador, Luis-Esteban...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S261-S262 , 2023

Link: https://doi.org/10.1016/..

12

OA-12 Predictors of unsustained measurable residual disease..:

Guerrero, Camila ; Puig, Noemi ; Cedena, Teresa...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S7-S8 , 2023

Link: https://doi.org/10.1016/..

13

P-053 Idecabtagene vicleucel (ide-cel) retreatment response..:

Wu, Fan ; Shen, Ye ; Zheng, Xirong...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S64 , 2023

Link: https://doi.org/10.1016/..

14

Disease Monitoring In Multiple Myeloma:

Hillengass, Jens ; Martin, Tom ; Puig, Noemi...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) 4 - p. 244-248 , 2023

Link: https://doi.org/10.1016/..

15

Integrated analysis of randomized controlled trials evaluat..:

Rosiñol, Laura ; Hebraud, Benjamin ; Oriol, Albert...
Frontiers in Oncology. 13 (2023) - p. , 2023

Link: https://doi.org/10.3389/..